ArticleEBioMedicine2015
Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure.
Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Unravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review.Dialogues in clinical neuroscience · 2026Pooled it
- Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder.Microbiology (Reading, England) · 2025Pooled it
- Gut microbiota composition in depressive disorder: a systematic review, meta-analysis, and meta-regression.Translational psychiatry · 2023Pooled it
- The Gut Microbiome in Psychosis From Mice to Men: A Systematic Review of Preclinical and Clinical Studies.Frontiers in psychiatry · 2020Pooled it
- Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials.Schizophrenia bulletin · 2022Trial
- The effects of probiotics plus dietary fiber on antipsychotic-induced weight gain: a randomized clinical trial.Translational psychiatry · 2022Trial
- Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial.PLoS medicine · 2020Trial
- Gut bacteriophage dynamics during fecal microbial transplantation in subjects with metabolic syndrome.Gut microbesTrial
- Gut Microbiota Modulation in CNS Disorders: Therapeutic Strategies and Implications for Drug Efficacy.Molecular neurobiology · 2026Review
- Antipsychotic-Induced Remodeling of the Gut Microbiota: Drug-Specific Patterns and Molecular Links to Metabolic Adverse Effects.International journal of molecular sciences · 2026Review
- Identifying Antibiotic Effects of Investigational Drugs on Commensal Bacteria with Machine Learning.ACS pharmacology & translational science · 2026Article
- Nutritional Management of Schizophrenia: Gut-Brain Axis Mechanisms and Dietary Interventions.Molecular neurobiology · 2026Review
- A taxon-centered review of bacterial shifts in psychiatric disorders.Frontiers in psychiatry · 2026Review
- Decoding psychotropic-induced metabolic disturbances: gut-brain axis, multi-omics, and nutrition-lifestyle integration.Frontiers in nutrition · 2026Review
- Gut microbiota and its association with gastrointestinal symptoms and pharmacological treatments in a sibling-matched cohort with autism spectrum disorder.Frontiers in microbiomes · 2026Article
- Reutericyclin, a specialized metabolite ofGut microbes · 2025Article
- Integrative evidence for causal links between gut microbiota and Schizophrenia: A Mendelian randomization and 16S rRNA study.Brain, behavior, & immunity - health · 2025Article
- The Microbiota-Gut-Brain Connection: A New Horizon in Neurological and Neuropsychiatric Disorders.CNS neuroscience & therapeutics · 2025Review
- Gut microbial contributions to thermogenesis.The Journal of experimental biology · 2025Review
- Reutericyclin mitigates risperidone-induced suppression of anaerobic energy expenditure.American journal of physiology. Regulatory, integrative and comparative physiology · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day) exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.